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Vitamin D may reduce mortality from prostate cancer (PC). We examined the associations of post-
treatment plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with PC 
mortality. Participants were PC cases from the New South Wales Prostate Cancer Care. All contactable 
and consenting participants, at 4.9 to 8.6 years after diagnosis, were interviewed and had plasma 
25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) measured in blood 
specimens. Cox regression allowing for left-truncation was used to calculate adjusted mortality hazards 
ratios (HR) and 95% confidence intervals (95% CI) for all-cause and PC-specific mortality in relation to 
vitamin D levels and other potentially-predictive variables. Of the participants (n = 111; 75·9% response 
rate), there were 198 deaths from any cause and 41 from PC in the study period. Plasma 25(OH)D 
was not associated with all-cause or PC-specific mortality (p-values > 0·10). Plasma 1,25(OH)2D was 
inversely associated with all-cause mortality (HR for highest relative to lowest quartile = 0·45; 95% CI: 
0·29–0·69), and PC-specific mortality (HR = 0·40; 95% CI: 0·14–1·19). These associations were apparent 
only in men with aggressive PC: all-cause mortality HR = 0·28 (95% CI·0·15–0·52; p-interaction = 0·07) 
and PC-specific mortality HR = 0·26 (95% CI: 0·07–1.00). Time spent outdoors was also associated with 
lower all-cause (HR for 4th relative to 1st exposure quartile = 0·42; 95% CI: 0·24–0·75) and PC-specific 
(HR = 0·48; 95% CI: 0·14–1·64) mortality, although the 95% CI for the latter was wide. The inverse 
association between post-treatment plasma 1,25(OH)2D levels and all-cause and PC-specific mortality 
in men with aggressive PC, suggest a possible beneficial effect of vitamin D supplementation in these 
men.
Prostate cancer (PC) is the most commonly diagnosed cancer and the third most common cause of cancer death 
in men in developed countries1. Although the five-year survival rate for prostate cancer is ~95%, it is the second 
most common cause of death in Australian men. It is estimated that in 2018, 1 in 31 Australian men will die from 
prostate cancer by their 85th birthday2. Thus, identifying modifiable factors that may improve a man’s survival 
after a prostate cancer diagnosis is important. There is some evidence that vitamin D may influence prostate can-
cer development and progression, and thus may be such a factor3.
The two main metabolites of vitamin D are the pro-hormone calcidiol (25(OH)D) which is converted to 
the biologically active hormone calcitriol (1,25(OH)2D) in a tightly regulated process. 1,25(OH)2D has 
anti-proliferative, pro-differentiating and pro-apoptotic properties on a range of cells and tissues, including 
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cancers. The pro-hormone, 25(OH)D, is stable and consequently more abundant in serum than 1,25(OH)2D and 
is thus used to infer vitamin D status. A circulating level of 25(OH)D above 50 nmol/L is generally considered 
sufficient while that for 1,25(OH)2D is not defined4.
High circulating 25(OH)D levels may improve PC survival5. Long term follow-up of men from the Health 
Professional Follow-up (HPFS) and Physicians Health (PHS) studies showed that men with pre-diagnosis cir-
culating 25(OH)D below 40nmol/L had higher PC-specific mortality than those with levels above 90nmol/L 
(HR = 1·59; 95% CI: 1·06, 2·39)6–9. This association was more evident in men with aggressive disease6,7. A small 
Norwegian study comparing blood specimens collected pre- and post-treatment showed a stronger association of 
post-treatment than pre-treatment vitamin D levels with outcome10, thus suggesting that post-diagnosis vitamin 
D status may be a better predictor of PC outcome than pre-diagnosis status.
Risks of both prostate cancer and vitamin D deficiency (<30 nmol/L) increase with advancing age. The devel-
opment of metastases, which are usually in bone, is led by the intercellular communication between PC cells and 
their microenvironment11. Studies in prostate cancer cell lines showed that vitamin D deficiency stimulates pros-
tate cancer growth in bone and have attributed this to possible changes in the bone microenvironment or through 
direct actions of the unliganded vitamin D receptor12. Two clinical trials in PC cases showed that although vita-
min D supplementation increased circulating 25(OH)D and 1,25(OH)2D levels in blood and tissue, reduced pro-
liferation in prostate cancer cells was only associated with increased 1,25(OH)2D levels13,14. These results suggest 
that (i) high 25(OH)D levels may induce intracrine activity in the prostate and reduce proliferation, and thus 
maintaining these high levels may prevent PC progression and improve survival, and (ii) that blood 1,25(OH)2D 
levels are a predictors of PC outcome. To fully understand the relationship between vitamin D and PC outcomes, 
the effects of both 25(OH)D and 1,25(OH)2D levels need to be analysed.
The primary objective of the current study was to examine the associations of plasma vitamin levels of 25(OH)
D and 1,25(OH)2D, after PC treatment with death from all-causes and death from PC in an Australian cohort of 
PC patients15. We also explored the associations of other factors previously shown to be associated with circu-
lating vitamin D levels with PC mortality. We hypothesised a positive association between circulating vitamin D 
levels and PC survival.
Materials and Method
Study population. Participants in the New South Wales (NSW) Prostate Cancer Care and Outcome Study 
(PCOS) were eligible to participate in the present study (PCOSun).
PCOS participants were residents of NSW identified through the NSW Cancer Registry as diagnosed with 
pathologically proven PC when aged 70 years or less between September 2000 and October 2002· Of these men, 
62% (n = 1,995) participated in PCOS15. PCOS participants were interviewed first at three months after PC diag-
nosis and reinvited for quality of life assessments at one, two, three, five, ten and fifteen years later. All PCOS par-
ticipants who remained contactable and had not actively withdrawn from PCOS by 2007 (n = 1572) were invited 
by letter to participate in PCOSun. Details of the study protocol have been published15.
Each man who accepted our invitation and gave written informed consent, was asked to complete an interview 
and given a request form to take to their nearest pathology specimen collection centre for collection of blood for 
measurement of plasma 25(OH)D and 1,25(OH)2D.
The Cancer Council NSW Human Research Ethics Committee (#217) approved this study.
Interview. The computer assisted telephone interview included questions on ethnicity, skin pigmentation, 
tanability, diet, vitamin D supplementation, and time spent outdoors between 9 am and 5 pm on weekends and 
weekdays or days-off in the 4 weeks before blood collection.
Plasma vitamin D analysis. Participants’ blood specimens were collected into EDTA tubes and processed 
within 48 hours of collection. All plasma samples were aliquoted and stored at −80 °C and analysed for 25(OH)
D and 1,25(OH)2D at the end of sample collection. Personnel at RDDT Laboratories (vivo Pharm Co. RMIT 
University, Melbourne, Australia) who were blinded to participant status performed all vitamin D analyses, 
according to their standard operating procedures (SOP). Analyses of 25(OH)D were carried out by high-pressure 
liquid chromatography-mass spectrometry (API 4000 QTRAP LC-MS/MS), which, according to RDDT’s proto-
col, has a sensitivity of 6·9 nmol/L for 25(OH)D3. All analyses were based on at least a 6-point standard calibration 
curve with a standard acceptance criterion of <20% for any given standard, with an intra-assay precision of <20% 
and an intra-assay accuracy of ±15%. Plasma 1,25(OH)2D was determined in duplicate using chemiluminescence 
immunoassay (IDS-iSYS,EIA Immuno Diagnostics Systems). The assay has a sensitivity of 6 pmol/L, and an 
intra-assay precision of <20%. The 1,25(OH)2D assay measured the dihydroxylated forms of both vitamin D2 
and vitamin D3·
Study endpoints. Participants’ personal details were linked probabilistically to the Australian National 
Death Index (compiled from death registration records) to determine vital status and, if dead, the cause of death. 
Linkage was complete to December 2015 for PCOS. Data were obtained on fact, date and registered cause of 
death.
Data analysis. Variables used in the analysis are detailed in Table 1· The residential Accessibility and 
Remoteness Index of Australia (ARIA plus), was derived from residential postcode, and used to classify each par-
ticipant’s place of residence16. The Index of Relative Socioeconomic Disadvantage was used as a measure of local 
government area socioeconomic status (SES), and ranked into population quintiles, with the lowest quintile the 
least disadvantaged17. Body Mass Index (BMI), based on self-reported measures of weight and height before PC 
diagnosis, was calculated as weight (kg)/[height (m)]2 and classified into the World Health Organisation’s stand-
ard groups. The few (n = 5) in the underweight category (<18·5 kg/m2) were combined with those in the “normal” 
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BMI group (18·5–24·9 kg/m2). Season of blood collection was defined as “Summer”, “Autumn”, “Winter” and 
“Spring” for bloods drawn between December and February, March and May, June and August, and September 
and November respectively.
Co-morbidity was categorised as having no self-reported co-morbid condition from the following list or hav-
ing one or more of these conditions: arthritis, diabetes, heart disease, stroke, high blood pressure, depression or 
anxiety, inflammatory bowel disease, stomach ulcers, asthma, angina or liver disease.
Men were classified as having aggressive or non-aggressive PC at diagnosis, according to the National 
Comprehensive Cancer Network criteria18, which classify clinically significant PC as aggressive if the Gleason 
score is >7, clinical stage is T2b or greater, total PSA levels are >10 ng/mL, or a regional lymph node or distant 
metastasis was found at diagnosis.
Weekly sun exposure hours were estimated by multiplying hours reported per weekday by five, and hours on 
weekend days or days off by two and summing them. Participants were ranked according to their hours of sun 
exposure and divided into quartiles for analysis; the lowest sun exposure quartile was used as the reference cat-
egory. Plasma 25(OH)D and 1,25(OH)2D levels were divided into quartiles, using the lowest category in each as 
the reference group. All quartiles were relative to the PCOSun population.
Men with missing data for covariates were excluded from analyses that required them.
Statistical analysis. Cox regression models allowing for left-truncation were used to calculate mortality 
hazards ratios (HR) and their 95% confidence intervals19. The underlying time scale for the Cox regression was 
time from diagnosis, with entry at the blood draw and exit at death, emigration or the end of follow-up, which-
ever came first. HRs were adjusted for age, place of residence, socioeconomic status, birth region, BMI, initial PC 
treatment, co-morbidity, PC aggressiveness and season of blood collection. We also examined, in separate Cox 
models, the associations of weekly outdoor exposure (estimator of UV exposure), skin colour and tanability with 
outcomes. The interactions of the main exposures of interest, which were plasma 25(OH)D and 1,25(OH)2D 
levels, sun exposure, ability to tan, and skin colour, with aggressiveness of disease, treatment and cohort (PCOS 
or ProsCan) were examined, and declared present if the p-value for interaction was <0·10. Nominal p-values are 
shown for each statistical test with no adjustments made for multiple comparisons. Frequencies in cells with less 
than 5 participants were not reported. All analyses were done using SAS software version 9·1.
Due to seasonal variation of vitamin D levels, season of blood collection is plausibly on a causal pathway 
between vitamin D and death, and thus a sensitivity analysis excluding season of blood collection from Cox 
models was conducted.
Ethics approval. All procedures performed in studies involving human participants were in accordance with 
the ethical standards of the institutional and national research committee - The Cancer Council NSW Human 
Research Ethics Committee (#217).
Informed consent. Informed consent was obtained from all individual participants included in the study.
Results
Of the eligible and consenting PCOS participants (n = 1194; participation rate 75.9%) 75 were excluded from the 
analysis because of missing data, leaving 1119 (86·7% of eligible and consenting) men in the final analysis (Fig. 1).
Median age at blood collection was 68 years (range 49 to 77 years), and median follow-up time after blood 
collection was 97 months. There were 198 deaths due to any cause during the study period of which 41 were 
certified to PC.
Plasma 25(OH)D and 1,25(OH)2D levels were positively correlated (Pearson correlation = 0.28; p-value < 
0.0001). Mean plasma 25(OH)D and 1,25(OH)2D levels were 66.0 nmol/L and 90.9 pmol/L, respectively (Table 1). 
Plasma 25(OH)D levels were higher in men who were born in Australia, were diagnosed with non-aggressive 
disease, received radiotherapy as primary treatment and had blood drawn in summer (Table 1; p-value < 0.05). 
They were also positively associated with increasing remoteness of residence, increasing time spent outdoors, 
and increasing ability to tan. Plasma 1,25(OH)2D levels (Table 1) were higher in men who were diagnosed with 
non-aggressive disease, received radiotherapy as primary treatment, had no comorbidities, and had blood drawn 
in autumn/winter (p-value < 0.05) and were economically advantaged. They were inversely associated with age 
and BMI. Vitamin D was not included in this analysis as only 2.4% of participants reported taking them.
There was no consistent evidence that plasma 25(OH)D was associated with all-cause or prostate-specific 
mortality (p-value > 0·1; Table 2). Plasma 1,25(OH)2D was significantly associated with all-cause mortality (HR 
for highest relative to lowest quartile = 0·45, 95% CI 0·29, 0·69; p = 0·0047; Table 2). While there was a similar 
trend for PC specific mortality (HR 0·40, 95% CI 0·14, 1·19; p = 0·26) the p-value was high. Weekly hours of out-
door exposure were also inversely associated with all-cause mortality (HR for highest relative to lowest quartile 
was 0·55, 95% CI: 0·36, 0·84; p = 0·053; Table 2). Adjustment for plasma 1,25(OH)2D did not appreciably change 
this inverse association. Skin colour and ability to tan were not associated with all-cause or PC-specific mortality.
The sensitivity analysis excluding season of blood collection from the regression did not appreciably change 
the size of the hazard ratios (results not shown).
Of the 30 interactions examined, only the p-value of that between 1,25(OH)2D levels and disease aggressive-
ness (p-interaction = 0·070) was relatively low. The association of 1,25(OH)2D with all-cause and PC-specific 
mortality appeared to be limited to men with aggressive disease (Table 3): all-cause mortality HR for highest rel-
ative to lowest quartile = 0·28 (95% CI: 0·15, 0·52) and corresponding PC-specific mortality HR = 0·26 (95% CI: 
0·07, 1.00). There was no strong or consistent pattern for an association of ability to tan with all-cause mortality 
or modification of this association by disease aggressiveness.
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Characteristics
Participants 25 OHD (SD)
1,25(OH)2D 
(SD) Deaths (n)
n (%) (nmol/L) (pmol/L) Total PC
All participants 1119 (100.0) 66.0 (21.3) 90.9 (34.7) 198 41
Region of birth
Australia 872 (77.9) 66.7 (21.0) 91.2 (35.0) 158 29
Other 247 (22.1) 63.5 (22.3) 89.8 (33.4) 40 12
P heterogeneity 0.039 0.57
Prostate cancer grade at diagnosis
Non-aggressive 528 (47.2) 68.6 (21.3) 93.7 (35.6) 82 11
Aggressive 591 (52.8) 63.7 (21.1) 88.4 (33.6) 116 30
P heterogeneity 0.0001 0.011
Primary Prostate cancer treatment
Active Surveillance† 120 (10.7) 65.6 (19.5) 85.1 (31.3) 26 NR‡
Radical prostatectomy 699 (62.5) 66.7 (20.9) 93.2 (34.0) 90 21
Low-dose brachytherapy 39 (3.5) 71.1 (19.3) 110.8 (39.7) 5 NR‡
External beam radiotherapy 65 (5.8) 67.9 (26.8) 93.7 (40.5) 13 NR‡
Androgen deprivation 
therapy†† 196 (17.5) 62.2 (22.0) 81.4 (32.9) 64 17
P heterogeneity 0.044 <0.0001
Comorbidities
None 435 (38.9) 66.1 (20.9) 96.7 (35.5) 65 14
1 or more 684 (61.1) 66.0 (21.6) 87.2 (33.6) 133 27
P heterogeneity 0.94 <0.0001
Season of blood draw
Spring 818 (73.1) 62.6 (19.9) 88.8 (34.7) 138 28
Summer 261 (23.3) 75.8 (22.5) 96.7 (34.2) 55 NR‡
Autumn & Winter 40 (3.6) 72.0 (20.2) 97.0 (33.6) 5 NR‡
p-value <0.00010.003 P 
heterogeneity <0.0001 0.003
Age at diagnosis (years)
49–54 152 (13.6) 69.8 (22.4) 101.0 (33.2) 15 5
55–59 271 (24.2) 66.2 (22.1) 93.7 (35.8) 34 9
60–64 319 (28.5) 65.2 (19.4) 87.9 (33.5) 47 14
65–85 377 (33.7) 65.1 (21.8) 87.3 (34.5) 102 13
P heterogeneity 0.11 <0.0001
Body Mass Index (BMI)
Underweight and normal 
weight 343 (30.7) 67.2 (22.8) 95.8 (37.2) 56 11
Overweight 555 (49.6) 66.3 (20.6) 90.5 (33.2) 94 19
Obese 221 (19.7) 63.3 (20.6) 84.5 (33.1) 48 11
P heterogeneity 0.092 0.00070
Socioeconomic status (SES)
1 (Most advantaged) 279 (24.9) 65.6 (20.9) 97.8 (37.0) 35 7
2 190 (17.0) 64.0 (20.6) 89.6 (34.7) 32 6
3 277 (24.8) 65.1 (20.4) 91.2 (33.7) 54 12
4 215 (19.2) 70.0 (23.6) 88.0 (33.2) 47 8
5 (least advantaged) 158 (14.1) 65.3 (20.8) 83.8 (32.1) 30 8
P heterogeneity 0.041 0.00060
Place of residence
Major cities 751 (67.1) 64.5 (20.9) 92.0 (35.7) 115 30
Inner regional 286 (25.6) 68.3 (21.2) 88.4 (32.4) 62 NR‡
Outer regional/Remote 82 (7.3) 72.4 (23.5) 89.5 (32.6) 21 NR‡
P heterogeneity 0.00070 0.30
Weekly hours of outdoor exposure
0–10·5 (inclusive) 255 (22.8) 59.562·7 (20.6) 87.2 (29.8)85·3 59 13
10·6–18.0 272 (24.3) 63.2 (20.4)66·5 94.2 (37.8)92·9 49 11
18.1–28.0 318 (28.4) 69.4 (20.0)71·5 92.6 (36.7)90·8 54 11
28.1–56·0 274 (24.5) 71.0 (22.4)73·6 89.1 (32.8)88·6 36 6
Continued
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In models with all variables as covariates, except vitamin D metabolite concentrations, (Table 4), mortality 
from all-causes was positively associated with age, treatment with androgen deprivation therapy, and Summer 
blood draw. Mortality from PC was positively associated with grade of disease at diagnosis- HR for aggressive PC 
relative to non-aggressive = 2·35 (95% CI: 1·17, 4·74, p-value 0·018).
Discussion
To the best of our knowledge, this is the first study to prospectively examine the association of post-treatment lev-
els of plasma vitamin D metabolites with death after a PC diagnosis. We found no significant association between 
plasma 25(OH)D levels and risk of death after a diagnosis of PC. Risk of death from all-causes and from PC fell 
with increasing plasma 1,25(OH)2D levels. These trends appeared to be restricted to men with aggressive disease.
Previous epidemiological studies have focussed mainly on the effect of pre-diagnosis circulating 25(OH)D lev-
els on mortality. They have consistently shown an inverse relationship between circulating pre-diagnosis 25(OH)
D levels and all-cause mortality with mixed evidence for PC-specific mortality6,7,9,20,21. One study that measured 
Characteristics
Participants 25 OHD (SD)
1,25(OH)2D 
(SD) Deaths (n)
n (%) (nmol/L) (pmol/L) Total PC
P heterogeneity <0.0001 0.07
Skin colour
Very fair 161 (14.4) 64.0 (20.1) 90.0 (35.5) NR‡ NR‡
Fair 637 (56.9) 65.9 (21.7) 90.0 (32.8) 113 23
Light olive 288 (25.7) 67.9 (21.0) 93.2 (38.2) 50 8
Dark olive/Brown/Black 33 (2.9) 62.0 (22.4) 92.6 (34.6) NR‡ NR‡
P heterogeneity 0.17 0.61
Ability to tan
Deeply tanned 326 (29.1) 70.4 (23.5) 89.9 (35.4) 51 10
Moderately tanned 521 (46.6) 64.5 (20.6) 91.4 (34.6) 94 19
Mildly/no suntan 272 (24.3) 63.6 (19.1) 91.1 (34.0) 53 12
P heterogeneity <0.0001 0.82
Table 1. Characteristics, mean plasma vitamin D levels and mortality outcomes of PCOSun* participants with 
complete data for analysis. *Follow up until December 2015 for NSW. †Includes watchful waiting. ††Includes 
orchiectomy. ‡Not reported (NR) as sample size in one of these cells has less than 5 men.











1 Reference 15 Smith DP et al BMJ 2009 Nov 27;339:b4817
2 Not in study due to death, le study or lost to follow-up
n2=423
Re-invited in 2008/10
Figure 1. Flow diagram showing final derivation of participants in the PCOSun cohort.
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post-treatment 25(OH)D levels, although small (37 participants with average time from treatment to blood col-
lection 2·4 years), reported lower PC-specific mortality in men with 25(OH)D levels above 50 nmol/L in both 
pre- and post-treatment bloods, but a stronger association with post-treatment levels. These results suggest that 
time after treatment may be important to any association of circulating vitamin D with death in men with PC10. 
A combined analysis of the HPFS and the PHS showed no evidence of an association between 1,25(OH)2D levels 
measured before diagnosis and all-cause or PC-specific mortality6.
The differences between our results and those previously reported may be explained by the complex associa-
tion between circulating 25(OH)D and 1,25(OH)2D. In young adults, the conversion of 25(OH)D to 1,25(OH)2D 
is tightly regulated, involving calcium and inorganic phosphate levels, as well as parathyroid (PTH) hormone 
actions. When circulating calcium levels are low, PTH levels are upregulated, which triggers the conversion of 
25(OH)D to 1,25(OH)2D, which in turn promotes the intestinal absorption of calcium to restore calcium bal-
ance. Results from the Malmo Study in PC patients showed that the association between 25(OH)D levels and 
PC-specific mortality was modified by PTH and serum calcium levels5. Our inability to address effect modifi-
cation by PTH or calcium, as we did not measure them, may explain some of the lack of association between 
25(OH)D and PC-specific mortality in this study. Another factor to consider is the high 25(OH)D levels in our 
population compared to other studies. Over 90% of our participants had their bloods drawn in the warmer 
months (September to February) when ambient UV levels are high, and even those who had bloods drawn in 
autumn or winter had mean levels well within the sufficiency range (>70 nmol/L), probably due to outdoor sun 
exposure. The “warmer” months may raise men’s vitamin D levels to similar levels for all men, thereby possibly 








Deaths (n) HR†(95% CI) Deaths (n) HR†(95% CI)
25 OHD (nmol/L)*
14.23–53·82 2357.4 70 1·00 15 1·00
53·82–66·09 2238.2 48 0·74 (0·51, 1·07) 14 1·10 (0·52, 2·31)
66·09–80·25 2030.8 37 0·66 (0·44, 0·99) 5 0·43 (0·15, 1.20)
80·25–174.68 1754.5 43 0·79 (0·52, 1·19) 7 0·81 (0·31, 2·12)
P heterogeneity 0·19 0·33
1,25(OH)2D*(pmol/L)*
4.84–67.24 1906.7 68 1·00 12 1·00
67.24–83·87 2085.2 49 0·76 (0·52, 1·10) 14 1·15 (0·52, 2·53)
83·87–106·56 2062.3 50 0·78 (0·54, 1·14) 10 0·84 (0·35, 2.01)
106·56–263.88 2326.6 31 0·45 (0·29, 0·69) 5 0·40 (0·14, 1·19)
P heterogeneity 0·0047 0·26
Weekly hours of outdoor exposure*
0.1–10·5 1856.1 59 1·00 13 1·00
10·5–18.0 2048.3 49 0·78 (0·53, 1·15) 11 0·83 (0·37, 1·86)
18.1–28.0 2373.0 54 0·74 (0·51, 1·08) 11 0·76 (0·33, 1·73)
28.1–56·0 2103.4 36 0·55 (0·36, 0·84) 6 0·43 (0·16, 1.14)
P heterogeneity 0·053 0·40
Skin colour
Very fair 1187.1 NR†† 1·00 NR†† 1·00
Fair 4771.5 113 0·92 (0·61, 1·36) 29 0·75 (0·33, 1·70)
Light olive 2171.9 50 0·93 (0·59, 1·47) 10 0·61 (0·23, 1·67)
Dark olive/Black 250.4 NR†† 0·51 (0·15, 1·70) NR†† 1·12 (0·23, 5·49)
P heterogeneity 0·75 0·75
Ability to tan
Deeply tanned 2452.1 51 0·82 (0·58 1·16) 10 0.89 (0·41, 1.93)
Moderately tanned 3926.7 94 1·00 19 1·00
Mildly/no tan 2002.1 53 1·11 (0·79, 1·56) 12 1·31 (0·63, 2·73)
P heterogeneity 0·32 0·65
Table 2. Adjusted mortality hazard ratios and 95% CI for deaths from all-causes and deaths from PC according 
to quartiles of plasma vitamin D and time spent outdoors, and categories of sun sensitivity in PCOSun 
participants (n = 1119). *Categories are quartiles of exposure. †Hazards ratio (HR) and 95% CI adjusted for 
study, age, place of residence, socioeconomic status, region of birth, BMI, PC treatment, PC grade at diagnosis, 
comorbidities, season of blood collection, and weekly hours of outdoor exposure. ††Not reported (NR) as 
sample size in one of these cells has less than 5 men.
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Age of blood draw and timing of PC therapy may also play an important role in regulating vitamin D levels. 
Although tightly regulated in the young, seasonal fluctuations in 1,25(OH)2D levels have been reported in elderly 
people, possibly due to calcium dysregulation as a consequence of decline in bone mineral density22–24. Seasonal 
variation in 1,25(OH)2D levels was evident in PCOSun participants whose mean age at blood collection was 
68 years. They were thus an older cohort than the Harvard cohorts (mean age 63 years in HPFS and 59 years in 
PHS)6. With regards to timing of blood collection relative to PC therapy, patients receiving androgen deprivation 
(ADT) and other adjuvant therapies are likely to experience disruption in their calcium homeostasis, which can 
result in loss of bone mineral density, and alter vitamin D status from the level it was before diagnosis to suit 
‘current conditions’. The median time to blood collection was 5 years post-diagnosis in PCOSun, where a propor-
tion of men had received primary treatment, whereas HPFS and PHS cohorts combined had blood specimens 














14.23–53.82 934.8 21 1·00 1422.6 49 1·00 10 1·00















P heterogeneity 0·99 0·15 0·67
1,25 OHD (pmol/L)*
4.84–67.24 881.4 20 1·00 1025.3 48 1·00 10 1·00





83·87–106·56 987.0 25 1·29 (0·70, 2·36) 1075.3 25
0·51 (0·31, 
0·84) NR
€ 0·47 (0·16, 
1·44)
106·56–263.88 1200.0 18 0·73 (0·38, 1·40) 1126.7 13
0·28 (0·15, 
0·52) NR
€ 0·26 (0·07, 
1.00)
P heterogeneity 0·34 0.00040 0.10
Time spent outdoors (hours)*
0–10·5 (inclusive) 833.3 20 1·00 1022.9 39 1·00 NR€ 1·00










28.1–56·0 994.1 17 0·70 (0·35, 1·39) 1109.3 19
0·42 (0·24, 
0·75) NR
€ 0·48 (0·14, 
1·64)
P heterogeneity 0·78 0·028 0·51
Skin colour
Very fair 527.7 NR€ 1·00 659.3 NR6 1·00 NR€ 1·00










Dark olive/Brown/Black 99.5 NR€ 0·46 (0·06, 3.61) 150.8 NR
6 0·54 (0·12, 
2.37) NR
€ 0·62 (0·07, 
5.58)
P heterogeneity 0·67 0·84 0·86
Ability to tan
Deeply tanned 1146.2 23 1·11 (0·65, 1·92) 1305.9 28
0·66 (0·42, 
1·04) NR
€ 0·45 (0·15, 
1·38)
Moderately tanned 1869.2 32 1·00 2057.5 62 1·00 16 1·00
Mildly/no suntan 961.7 27 1·75 (1·02, 3·00) 1040.3 26
0·83 (0·52, 
1·33) NR
€ 1·55 (0·68, 
3·54)
P heterogeneity 0·11 0·20 0·13
Table 3. Adjusted mortality hazard ratios and 95% CI for deaths from all-causes according to quartiles of 
plasma vitamin D and time spent outdoors, and categories of sun sensitivity in PCOSun participants (n = 1119), 
stratified by PC aggressiveness. *Categories are quartiles of exposure. †PC-specific mortality was not computable 
due to the small number of PC deaths in this category. ††Hazards ratio (HR) and 95% CI% CI adjusted for age, 
place of residence, socioeconomic status, region of birth, comorbidity, BMI, study, weekly outdoor exposure, 
season of blood collection and treatment (radical prostatectomy or other). ‡All-cause mortality. ¥PC-specific 
mortality. €Not reported (NR) as sample size in one of these cells has less than 5 men.











Age at diagnosis (years)
49–54 1161.9 15 1·00 5 1·00
55–59 2090.5 34 1·26 (0·68, 2.31) 9
0·95 (0·32, 
2.85)
60–64 2420.6 47 1·36 (0·75, 2·46) 14
1.13 (0·40, 
3.22)
65–85 2707.8 102 2·67 (1·52, 4.67) 13
0·97 (0·33, 
2.85)
P heterogeneity <0·0001 0·97
Place of residence
Major cities 5690.4 115 1·00 30 1·00
Inner regional 2078.0 62 1·35 (0.96, 1·92) NR
‡ 0·54 (0·23, 
1·29)
Outer regional/Remote 612.4 21 1·36 (0·82, 2·26) NR
‡ 0·92 (0·30, 
2·79)
P heterogeneity 0·19 0·38
Socioeconomic status (SES)
1 (Most advantaged) 2136.9 35 1·00 7 1·00
2 1428.6 32 1·26 (0·78, 2.06) 6
1·28 (0·42, 
3.85)
3 2056.3 54 1·26 (0·79, 1·99) 12
1·85 (0·70, 
4.93)
4 1581.7 47 1·33 (0·81, 2.16) 8
1·80 (0·61, 
5.32)
5 (least Most advantaged) 1177.3 30 1·28 (0·75, 2.17) 8
2.39 (0·81, 
7.06)
P heterogeneity 0·83 0·57
Region of birth
Australia 6523.9 158 1·00 29 1·00
Other 1856.9 40 0.97 (0·68, 1·38) 12
1·33 (0·66, 
2·68)
P heterogeneity 0·85 0·42
Body Mass Index (BMI)
Under & Normal weight 2573.0 56 1·00 11 1·00
Overweight 4176.7 94 1·07 (0·76, 1·50) 19
1·02 (0·48, 
2·17)
Obese 1631.1 48 1·46 (0·98, 2·19) 11
1·28 (0·53, 
3·07)
P heterogeneity 0·14 0·82
PC grade at diagnosis
Non-aggressive 3977.1 82 1·00 11 1·00
Aggressive 4403.7 116 1·30 (0·97, 1·73) 30
2·35 (1·17, 
4·74)
P heterogeneity 0.075 0·018
PC Treatment
Active Surveillance† 877.6 26 1·56 (0.98, 2·47) NR
‡ 0.72 (0·16, 
3·20)






External beam radiotherapy 473.3 13 1·13 (0·62, 2·06) NR
‡ 0·46 (0·06, 
3.49)
Androgen deprivation therapy†† 1370.9 64 2·17 (1·53, 3·06) 17
2.47 (1.23, 
4.94)
P heterogeneity 0.0003 0·074
Comorbidities
0 3290.1 65 1·00 14 1·00
1 or more 5090.7 133 1·05 (0·77, 1·44) 27
1·15 (0·58, 
2.27)
P heterogeneity 0·75 0.68
Season of blood draw
Continued
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PC treatment partly explains our findings for an association between 1,25(OH)2D and PC mortality, that has not 
been observed in other studies.
That higher plasma 1,25(OH)2D levels might reduce PC-specific mortality in PC cases with aggressive disease 
was unexpected. Fang and co-workers from the HPFS and PHS reported a link between 25(OH)D deficiency and 
higher mortality only in men with aggressive PC, but they found no association with 1,25(OH)2D6. A similar 
analysis of Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study reported increased PC-specific mortality 
in men with lower 25(OH)D, but no material difference in this association between men who had aggressive 
disease and those who did not6,7. The distinction between non-aggressive and aggressive PC is generally an inter-
mediate to high risk of metastasis in the latter and a negligible to low risk of metastasis in the former25,26. The 
development of metastasis, which is usually to the bone, is led by the intercellular communication between PC 
cells and their microenvironment11. Both in vivo and in vitro studies have shown that the anti-proliferative effect 
of 1,25(OH)2D in influencing the interaction between tumour and its microenvironment is androgen-dependent 
and varies by disease aggressiveness26. Two clinical trial of cholecalciferol in PC patients showed a lowering in 
PSA levels, number of positive cores and cell proliferation in cases who received vitamin D supplementation13,14. 
They further reported associations between several tumour suppressive micro ribonucleic acids (miR-126-3p, 
miR-154-5p and miR-21-5p), an miR processing ribonuclease (DICER-1), and elevated levels of 1,25(OH)2D. 
This tumour suppressive miR and DICER-1 are known to be associated with reduced risk of PC recurrence thus 
suggesting that 1,25(OH)2D may alter the microenvironment to regulate the interaction between stroma and 
epithelium in prostate tissue in a pathway involving miRs27,28. This potential for 1,25(OH)2D to influence both 
intracellular and microenvironment activities may explain our finding for a significant effect of 1,25(OH)2D only 
in PC cases with aggressive disease.
In all the studies referred to above, the apparently beneficial effects of 25(OH)D were specific to PC death. 
In contrast, we observed evidence that 1,25(OH)2D protected against death from all causes. Levels 25OHD and 
1,25(OH)2D are mainly regulated by PTH and calcium, with reducing dietary calcium lowering circulating 1,25D 
level, and increasing vitamin D intake and sun exposure increasing 1,25(OH)2D levels29. Few food products in 
Australia, however, naturally contain vitamin D or are fortified with it30, thus, it is unlikely that adequate intake 
of vitamin D is achievable here through diet modification alone, which then raises the potential for supplemen-
tation. Meta-analyses of vitamin D randomised trials reported a small reduction in total cancer mortality, but 
not incidence, in men and women supplemented with vitamin D (HR = 0·88; 95% CI: 0·78–0·98)31,32. Thus, an 
effect of high 1,25(OH)2D levels to reduce mortality from a number of cancers, including PC, is plausible, and 
consistent with other evidence of mortality benefits from vitamin D supplementation31,32. Two small clinical 
trials in PC patients showed the potential for vitamin D supplementation to reduce disease progression, but this 
may only have been achieved by high dose supplementation13,14. The duration of these trials however was too 
short to draw any conclusions on reducing mortality. Nonetheless, these studies raise the possibility that vitamin 
D-supplementation is beneficial in treating PC. There are currently a few clinical trials in progress that are explor-
ing the long-term benefits of high dose vitamin D supplementation in PC patients33,34.
Our study has several strengths. Blood specimens were drawn well after the patients had completed primary 
treatment; the reasonably long follow-up thereafter reduced, but does not eliminate, the possibility of reverse 
causation explaining the apparent effects of 1,25(OH)2D on PC mortality. Most studies have used pre-diagnostic 
circulating vitamin D levels to predict PC risk. Low vitamin D levels, however, may be a consequence of the 
cancer, in that the cancer may cause lethargy leading to spending less time outdoors and consequently lower-
ing vitamin D levels. Collecting blood some years after primary should have mitigated this effect. We used the 
National Comprehensive Cancer Network criteria for classifying PC as aggressive or not18. These criteria are 
consistent with how clinicians define aggressive disease and provide a comprehensive measure. The study’s main 
limitation is the small number of deaths from PC (n = 41), which limits the statistical power for detecting effects 
on prostate-specific mortality, and the lack of measurement of blood calcium and parathormone. Additionally, we 
chose not to adjust for multiple comparisons and, instead to evaluate the results in the context of prior evidence, 
biological plausibility, the number of tests performed, and the strengths of the observed associations, as recom-
mended by several relevant experts35–37. While p-values are nominal for individual tests, the Type I error rate is 










Spring 6195.8 138 1·00 28 1·00
Summer 1891.9 55 1·54 (1·12, 2.12) NR
‡ 1·34 (0·66, 
2·74)
Autumn&Winter 293.2 5 0.94 (0·38, 2·32) NR
‡ 1.98 (0·45, 
8.67)
P heterogeneity 0.029 0.53
Table 4. Adjusted mortality hazard ratios1 and 95% CI for deaths from all-causes and deaths from PC, 
according to PCOSun participant characteristics other than plasma vitamin D concentrations (n = 1119). 
*Hazards ratio (HR) and 95% CI adjusted for study, age, place of residence, SES, region of birth, BMI, PC 
treatment, PC grade at diagnosis, season of blood collection and comorbidities. †Includes watchful waiting. 
††Includes orchiectomy. ‡Not reported (NR) as sample size in one of these cells has less than 5 men. ¥Not 
computable (NC) as numbers of treatment-specific PC deaths are too small.
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Our results suggest that high plasma 1,25(OH)2D after PC diagnosis and treatment may decrease all cause 
and PC-specific mortality, particularly in men with aggressive PC. With few known risk factors for PC identified 
to date, the results from this study suggests there may be prognostic value in post-diagnostic circulating levels of 
vitamin D for survival from aggressive PC, and possibly therapeutic value as well. These possibilities merit further 
research.
Data availability
Some access restrictions apply to the data underlying this study’s findings. The original human ethics committee 
approval for PCOS did not allow for data to be sent outside Australia. Furthermore, the PCOSun participants have 
not consented to their data being distributed beyond the PCOSun Investigators and their associates. Qualified 
researchers may submit a request to the corresponding author (visalinin@nswcc.org.au) and access will require 
additional ethics approval from the Cancer Council NSW HREC, including considerations of privacy for data 
sharing.
Received: 28 June 2019; Accepted: 2 March 2020;
Published: xx xx xxxx
References
 1. Ahn, J. et al. Vitamin D in Prostate Cancer. Vitamins and hormones 100, 321–355, https://doi.org/10.1016/bs.vh.2015.10.012 (2016).
 2. Prostate cancer in Australia, https://prostate-cancer.canceraustralia.gov.au/statistics. Australian Institute of Health and Welfare; 
Date accessed: 19 November (2019).
 3. Banks, M. & Holick, M. F. Molecular Mechanism(s) Involved in 25-Hydroxyvitamin D’s Antiproliferative Effects in CYP27B1-
transfected LNCaP Cells. Anticancer research 35, 3773–3779 (2015).
 4. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin, D. & Calcium. In Dietary Reference Intakes for 
Calcium and Vitamin D (eds. Ross, A. C., Taylor, C. L., Yaktine, A. L. & Del Valle, H. B.) (National Academies Press (US) National 
Academy of Sciences., (2011).
 5. Brandstedt, J., Almquist, M., Manjer, J. & Malm, J. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested 
case-control study. Cancer causes & control: CCC 23, 1377–1385, https://doi.org/10.1007/s10552-012-9948-3 (2012).
 6. Fang, F. et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PloS one 6, e18625, 
https://doi.org/10.1371/journal.pone.0018625 (2011).
 7. Mondul, A. M., Weinstein, S. J., Moy, K. A., Mannisto, S. & Albanes, D. Circulating 25-Hydroxyvitamin D and Prostate Cancer 
Survival. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored 
by the American Society of Preventive Oncology 25, 665–669, https://doi.org/10.1158/1055-9965.epi-15-0991 (2016).
 8. Robsahm, T. E., Schwartz, G. G. & Tretli, S. The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: 
Discussion of Causation. Cancers 5, 1439–1455, https://doi.org/10.3390/cancers5041439 (2013).
 9. Shui, I. M. et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-
control study. Journal of the National Cancer Institute 104, 690–699, https://doi.org/10.1093/jnci/djs189 (2012).
 10. Tretli, S., Hernes, E., Berg, J. P., Hestvik, U. E. & Robsahm, T. E. Association between serum 25(OH)D and death from prostate 
cancer. British journal of cancer 100, 450–454, https://doi.org/10.1038/sj.bjc.6604865 (2009).
 11. Chung, L. W., Baseman, A., Assikis, V. & Zhau, H. E. Molecular insights into prostate cancer progression: the missing link of tumor 
microenvironment. The Journal of urology 173, 10–20, https://doi.org/10.1097/01.ju.0000141582.15218.10 (2005).
 12. Zheng, Y. et al. Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through 
downregulation of Wnt/beta-catenin signaling. Bone research 5, 17023, https://doi.org/10.1038/boneres.2017.23 (2017).
 13. Marshall, D. T. et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive 
cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. The Journal of clinical endocrinology and 
metabolism 97, 2315–2324, https://doi.org/10.1210/jc.2012-1451 (2012).
 14. Wagner, D. et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate 
cancer patients. The Journal of clinical endocrinology and metabolism 98, 1498–1507, https://doi.org/10.1210/jc.2012-4019 (2013).
 15. Smith, D. P. et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ (Clinical 
research ed.) 339, b4817, https://doi.org/10.1136/bmj.b4817 (2009).
 16. Australian Bureau of Statistics. ASGC Remoteness Classifi cation: purpose and use.Canberra:Commonwealth of Australia 2003, 
http://www.abs.gov.au/websitedbs/d3110122nsf/0/f9c96fb635cce780ca256d420005dc02/$FILE/Remoteness_Paper_text_final.pdf 
Date acccessed: 19 November (2019).
 17. Yu, X. Q., O’Connell, D. L., Gibberd, R. W. & Armstrong, B. K. Assessing the impact of socio-economic status on cancer survival in 
New South Wales, Australia 1996-2001. Cancer causes & control: CCC 19, 1383–1390, https://doi.org/10.1007/s10552-008-9210-1 
(2008).
 18. National Comprehensive Cancer Network. Prostate Cancer (Version 3·2018) June 2018. 2018, https://www.nccn.org/professionals/
physician_gls/pdf/prostate.pdf. Date acccessed: 19 November (2019).
 19. Howards, P. P., Hertz-Picciotto, I. & Poole, C. Conditions for bias from differential left truncation. American journal of epidemiology 
165, 444–452 (2007).
 20. Holt, S. K. et al. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer epidemiology 37, 666–670, https://
doi.org/10.1016/j.canep.2013.07.005 (2013).
 21. Meyer, H. E., Robsahm, T. E., Bjorge, T., Brustad, M. & Blomhoff, R. Vitamin D, season, and risk of prostate cancer: a nested case-
control study within Norwegian health studies. The American journal of clinical nutrition 97, 147–154, https://doi.org/10.3945/
ajcn.112.039222 (2013).
 22. Bouillon, R. A., Auwerx, J. H., Lissens, W. D. & Pelemans, W. K. Vitamin D status in the elderly: seasonal substrate deficiency causes 
1,25-dihydroxycholecalciferol deficiency. The American journal of clinical nutrition 45, 755–763, https://doi.org/10.1093/
ajcn/45.4.755 (1987).
 23. Hirani, V. et al. Low levels of 25-hydroxy vitamin D and active 1,25-dihydroxyvitamin D independently associated with type 2 
diabetes mellitus in older Australian men: the Concord Health and Ageing in Men Project. Journal of the American Geriatrics Society 
62, 1741–1747, https://doi.org/10.1111/jgs.12975 (2014).
 24. Rapuri, P. B., Kinyamu, H. K., Gallagher, J. C. & Haynatzka, V. Seasonal changes in calciotropic hormones, bone markers, and bone 
mineral density in elderly women. The Journal of clinical endocrinology and metabolism 87, 2024–2032, https://doi.org/10.1210/
jcem.87.5.8475 (2002).
 25. Gardiner, R. A. et al. In Chapter 10 Endotext.com 1–52 (South Dartmouth (MA), Inc 2018).
 26. Hagglof, C. & Bergh, A. The stroma-a key regulator in prostate function and malignancy. Cancers 4, 531–548, https://doi.
org/10.3390/cancers4020531 (2012).
1 1Scientific RepoRtS |         (2020) 10:7736  | https://doi.org/10.1038/s41598-020-62182-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 27. Dambal, S. et al. microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma. The Journal of steroid 
biochemistry and molecular biology 167, 192–202, https://doi.org/10.1016/j.jsbmb.2017.01.004 (2017).
 28. Giangreco, A. A. et al. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma 
and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. The Journal of steroid biochemistry 
and molecular biology 148, 156–165, https://doi.org/10.1016/j.jsbmb.2014.10.004 (2015).
 29. Chan, J. M. et al. Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. The American journal of clinical 
nutrition 74, 549–554, https://doi.org/10.1093/ajcn/74.4.549 (2001).
 30. Food Standards Australia New Zealand (FSANZ) (2011) NUTTAB Vitamin D file, http://www.foodstandards.gov.au/science/
monitoringnutrients/nutrientables/Pages/default.aspx (accessed December 2019).
 31. Keum, N. & Giovannucci, E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. British journal of cancer 
111, 976–980, https://doi.org/10.1038/bjc.2014.294 (2014).
 32. Keum, N., Lee, D. H., Greenwood, D. C., Manson, J. E. & Giovannucci, E. Vitamin D Supplements and Total Cancer Incidence and 
Mortality: a Meta-analysis of randomized controlled trials. Annals of oncology: official journal of the European Society for Medical 
Oncology, https://doi.org/10.1093/annonc/mdz059 (2019).
 33. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371904 Date accessed: 16 January (2019).
 34. https://clinicaltrials.gov/ Date accessed: 16 January (2019).
 35. Perneger, T. V. What’s wrong with Bonferroni adjustments. BMJ (Clinical research ed.) 316, 1236–1238, https://doi.org/10.1136/
bmj.316.7139.1236 (1998).
 36. Rothman, K. J. No adjustments are needed for multiple comparisons. Epidemiology (Cambridge, Mass.) 1, 43–46 (1990).
 37. Savitz, D. A. & Olshan, A. F. Multiple comparisons and related issues in the interpretation of epidemiologic data. American journal 
of epidemiology 142, 904–908, https://doi.org/10.1093/oxfordjournals.aje.a117737 (1995).
Acknowledgements
We would like to acknowledge Ms. Jennifer Rodger for her assistance in data collection for the PCOSun study, 
and Prof. Robyn Lucas and Ms. Renee Foo Le Ping for providing feedback on this manuscript. National Health 
and Medical Research Project grant (APP464850). D. Smith was supported by a grant from Cancer Institute NSW 
(#15/CDF/1-10).
Author contributions
V.N.S. participated in the conception and design of the study, collection and assembly of data from cases, data 
collection and analysis and interpretation and manuscript writing, and critically reviewed and approved the final 
version. A.B., S.E. and M.C. contributed to the statistical analysis and data interpretation, commented on drafts 
of the manuscript and critically reviewed and approved the final version; B.K.A., D.P.S., R.A.G., M.J.S., M.G.K., 
A.K., S.K.C. participated in conception, design and oversight of data collection of both studies, and interpretation 
of data and drafting the paper, and critically reviewed and approved the final version.
Competing interests
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to V.N.-S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
